Patents Examined by James Martinell
  • Patent number: 10435750
    Abstract: The present invention relates to the technical field of organ and tissue transplantation and specifically to methods allowing rejection of transplanted organs and tissues by a transplant patient. The present invention provides methods for non-invasive and ex vivo or in vitro detection of the presence or absence of transplant rejection, i.e. transplant health or rejection. The present methods allow for effective and continuous monitoring of transplant status with a minimal or absent discomfort for a transplant patient.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: October 8, 2019
    Assignee: MULTIPLICOM N.V.
    Inventors: Dirk Goossens, Joachim De Schrijver, Jurgen Del Favero
  • Patent number: 10428385
    Abstract: The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5% of the SNPs can be disregarded.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: October 1, 2019
    Assignee: PHADIA AB
    Inventors: Henrik Grönberg, Martin Eklund
  • Patent number: 10431326
    Abstract: The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: October 1, 2019
    Assignee: PHADIA AB
    Inventors: Henrik Grönberg, Martin Eklund
  • Patent number: 10422004
    Abstract: The invention provides methods for diagnosing eosinophilic esophagitis in a patient using a biomarker based assay directed to KCNJ2/Kir2.1 and related compositions, kits, and computer program products.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 24, 2019
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Marc E. Rothenberg, Ting Wen, Seema Aceves
  • Patent number: 10415093
    Abstract: Methods for diagnosing or monitoring endometriosis in a mammal are provided. The methods include the steps of determining the expression levels of BDNF and its receptor, Ntrk2, in a biological sample from the mammal, and determining that the mammal has endometriosis when the BDNF and Ntrk2 expression levels in the sample are elevated.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: September 17, 2019
    Assignees: MCMASTER UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Warren Foster, Nicholas Leyland, Jocelyne Wessels, Sanjay Agarwal
  • Patent number: 10391493
    Abstract: A system and method for isolating and analyzing single cells, wherein the system includes: an array of wells defined at a substrate, each well including an open surface and a well cavity configured to capture cells in one of a single-cell format and single-cluster format, and a fluid delivery module including a fluid reservoir superior to the array of wells through which fluid flow is controlled along a fluid path in a direction parallel to the broad face of the substrate; and wherein the method includes: capturing a population of non-cell particles into the array of wells in single-particle format; releasing, from the non-cell particles, a set of probes into the array of wells; capturing a population of cells into the array of wells in single-cell format; releasing biomolecules from each captured cell into the array of wells; and generating a set of genetic complexes comprising the biomolecules associated with a single captured cell and a subset of probes within individual wells of the array of wells.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Celsee Diagnostics, Inc.
    Inventors: Kalyan Handique, Vishal Sharma
  • Patent number: 10391492
    Abstract: A system and method for isolating and analyzing single cells, wherein the system includes: an array of wells defined at a substrate, each well including an open surface and a well cavity configured to capture cells in one of a single-cell format and single-cluster format, and a fluid delivery module including a fluid reservoir superior to the array of wells through which fluid flow is controlled along a fluid path in a direction parallel to the broad face of the substrate; and wherein the method includes: distributing a population of cells and a population of non-cell particles across the array of wells through the fluid reservoir to increase capture efficiency of individual cell-particle pairs within the array of wells, and processing the captured cell-particle pairs at the set of wells.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Celsee Diagnostics, Inc.
    Inventors: Kalyan Handique, Vishal Sharma, Priyadarshini Gogoi, William Chow, Austin Payne, Kyle Gleason, Brian Boniface, John Connolly, Sam Tuck
  • Patent number: 10385389
    Abstract: The invention relates to new methods of attaching one or more polynucleotide binding proteins to a target polynucleotide. The invention also relates to new methods of characterizing target polynucleotides.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 20, 2019
    Assignee: Oxford Nanopore Technologies Ltd.
    Inventors: Andrew John Heron, Clive Gavin Brown, Rebecca Victoria Bowen, James White, Daniel John Turner, Joseph Hargreaves Lloyd, Christopher Peter Youd
  • Patent number: 10364465
    Abstract: The disclosure provides a plurality of nucleic acid sequences comprising multiple variants of a reference sequence. The disclosure further provides plasmids, cells, methods and kits comprising the same.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 30, 2019
    Assignee: Life Technologies Corporation
    Inventors: Mona Shahbazian, Kara Norman, Aron Lau, Nakul Nataraj
  • Patent number: 10364472
    Abstract: The present invention discloses a method for identifying Wuzhishan miniature pig inbred line by using 145 SNPs. The method for auxiliarily identifying whether a pig to be tested is Wuzhishan miniature pig inbred line, provided by the present invention, comprises the following steps: testing genotypes based on 145 SNP sites of the pig to be tested; if all standards of (1) to (145) are satisfied, the pig to be tested is a candidate for Wuzhishan miniature pig inbred line; if all the standards of the above (1) to (145) are not satisfied, the pig to be tested is a candidate for non-Wuzhishan miniature pig inbred line.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: July 30, 2019
    Assignee: GRAND LIFE SCIENCE & TECHNOLOGY, LTD.
    Inventors: Shutang Feng, Yulian Mu, Jianlin Han, Kui Li, Qian Gao
  • Patent number: 10351845
    Abstract: The present invention comprises generally applicable methods for identifying endogenous physiologically relevant genetic elements that affects a intracellular phenotype of interest. In the methods, non-living cells that have been subjected to a mutagenesis treatment are sorted based on phenotype and analyzed to identify the genetic element. By use of these methods, elements previously unknown to be involved in a phenotype can be identified, for example in relationship to health conditions, external stress or drug response, in particular in cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 16, 2019
    Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Thijn Reinout Brummelkamp, Joppe Daniël Maria Nieuwenhuis, Lucas Tilmann Jae, Markus Brockmann, Vincent Arthur Blomen, Matthijs Raaben
  • Patent number: 10351910
    Abstract: Adherent stromal cells cultured under three dimensional conditions are provided, characterized, and distinguished from adherent stromal cells cultured under two dimensional conditions.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 16, 2019
    Assignee: PLURISTEM LTD
    Inventors: Rachel Ofir, Eytan Abraham
  • Patent number: 10350570
    Abstract: Provided herein are methods and compositions for placing single target molecules on a patterned substrate.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: July 16, 2019
    Assignee: ILLUMINA, INC.
    Inventors: Kevin L. Gunderson, Jingwei Bai, Boyan Boyanov
  • Patent number: 10344332
    Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: July 9, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Purvesh Khatri, Timothy E. Sweeney
  • Patent number: 10344321
    Abstract: The present invention relates to methods and devices for identifying and quantifying, including low abundance, nucleotide base mutations, insertions, deletions, translocations, splice variants, miRNA variants, alternative transcripts, alternative start sites, alternative coding sequences, alternative non-coding sequences, alternative splicings, exon insertions, exon deletions, intron insertions, or other rearrangement at the genome level and/or methylated nucleotide bases.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: July 9, 2019
    Assignee: Cornell University
    Inventors: Francis Barany, John William Efcavitch, Cristian Ruiz Rueda, Jianmin Huang, Philip B. Feinberg
  • Patent number: 10338066
    Abstract: Some embodiments disclosed herein provide a plurality of compositions each comprising a protein binding reagent conjugated with an oligonucleotide. The oligonucleotide comprises a unique identifier for the protein binding reagent it is conjugated with, and the protein binding reagent is capable of specifically binding to a protein target. Further disclosed are methods and kits for quantitative analysis of a plurality of protein targets in a sample and for simultaneous quantitative analysis of protein and nucleic acid targets in a sample. Also disclosed herein are systems and methods for preparing a labeled biomolecule reagent, including a labeled biomolecule agent comprising a protein binding reagent conjugated with an oligonucleotide.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: July 2, 2019
    Assignee: Cellular Research, Inc.
    Inventors: Christina Fan, Olaf Zoellner
  • Patent number: 10325675
    Abstract: The invention provides methods for identifying rare variants near a structural variation in a genetic sequence, for example, in a nucleic acid sample taken from a subject. The invention additionally includes methods for aligning reads (e.g., nucleic acid reads) to a reference sequence construct accounting for the structural variation, methods for building a reference sequence construct accounting for the structural variation or the structural variation and the rare variant, and systems that use the alignment methods to identify rare variants. The method is scalable, and can be used to align millions of reads to a construct thousands of bases long, or longer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 18, 2019
    Assignee: Seven Bridges Genomics Inc.
    Inventor: Deniz Kural
  • Patent number: 10323272
    Abstract: The invention provides nucleic acid hybridization probes having improved detectability that include a plurality of first segments consecutively complementary to a target nucleic acid sequence and, between neighboring first segments, a nucleic acid spacer segment which is not complementary to the target nucleic acid sequence and which may include labeled nucleic acid residues. Also provided by the invention are methods for making the probes, methods for using the probes, and compositions of matter that include the probes hybridized to target nucleic acid molecules.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: June 18, 2019
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jack Coleman, Maurizio Mauro
  • Patent number: 10316367
    Abstract: The present invention is directed to methods for diagnosing breast cancer, metastasizing breast cancer, or for determining the CTC status in a subject. Moreover, the present invention is concerned with devices and kits for carrying methods of the invention. The methods comprise determining in a sample of a subject suspected to be afflicted with breast cancer the amount of at least one miRNA selected from a recited list of miRNAs, followed by comparing the amount with one or more references, whereby breast cancer is to be diagnosed.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: June 11, 2019
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Barbara Burwinkel, Katarina Cuk, Manuela Zucknick, Dharanija Madhavan
  • Patent number: 10308982
    Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: June 4, 2019
    Assignee: Prognosys Biosciences, Inc.
    Inventor: Mark S. Chee